BACKGROUND : A recent clinical trial has demonstrated that patients with acute coronary syndromes ( ACS ) and the reduced function allele CYP2C19 * 2 ( * 2 allele ) , who are treated with thienopyridines , have an increased risk of adverse cardiac events with clopidogrel , but not with prasugrel .